Achieving Market Dominance Through Reformulation: A Strategic Insight

 

More than $165bn in ethical revenues may be cannibalised as a consequence of patent expiry from 31 leading drug patent expirations between 2000 and 2005. In view of this, pharmaceutical reformulation represents a viable option to maintain market leadership for key drugs. Achieving Market Dominance Through Reformulation: A strategic insight, provides a detailed analysis of the drug reformulation arena with emphasis on achieving and sustaining market dominance for new formulations through co-development and marketing. The report will help you develop a focused, well-planned reformulation strategy involving R&D, investment, partnering, and marketing that is crucial for long-term commercial reformulation success.

Additional Information

More than $165bn in ethical revenues may be cannibalised as a consequence of patent expiry from 31 leading drug patent expirations between 2000 and 2005.In view of this, pharmaceutical reformulation represents a viable option to maintain market leadership for key drugs.

Achieving Market Dominance Through Reformulation: A strategic insight, provides a detailed analysis of the drug reformulation arena with emphasis on achieving and sustaining market dominance for new formulations through co-development and marketing. The report will help you develop a focused, well-planned reformulation strategy involving R&D, investment, partnering, and marketing that is crucial for long-term commercial reformulation success.

A Practical Guide

Achieving Market Dominance Through Reformulation: A strategic insight provides you with

• A comprehensive account of the reformulation opportunities and oversights affecting 31 leading drugs that are scheduled to lose patent protection between 2000 and 2005
• Interviews with industry leaders discussing the advantages and pitfalls of this method of lifecycle management, highlighting successful reformulation strategies
• An overview of leading multinationals with a strong reformulation focus.The chapter also indicates the vast potential for multinationals to reformulate drugs but also indicates that the majority are under-achieving in this regard.